Can we consider CefTRIAXone contraindicated in Sickle Cell Anemia patients?

Immune hemolytic anemia has occurred in patients receiving cephalosporins, including CefTRIAXone.

Mechanism: Non dose-related; immunologic (ie, induces complement activating drug-dependent antibodies [mainly IgM-type] resulting in immune-complexes).

Onset: Varied; occurs several minutes to 7 days after the first dose (Ref).

Risk factors:

• Pediatric patients

• Sickle cell disease

• Cross-reactivity with other cephalosporins.

CefTRIAXone contraindicated in hyperbilirubinemic neonates and neonates